Showing results (181-190 of 208) with videos related to
Sort By:
Pageof 21
Hemasphere|April 21, 2020
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL NetworkDaniela Drandi, Marion Alcantara, Ichrafe Benmaad, et al.Frontiers in Oncology|May 29, 2026
Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scansMatthieu Delaye, Littisha Lawrance, Younes Belkouchi, et al.The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 2025
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC RegistryThomas Hueso, Justin Cagnat, Kaïssa Ouali, et al.Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaPhilippe Armand, Scott Rodig, Vladimir Melnichenko, et al.Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.Hematological Oncology|October 17, 2022
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphomaCarmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, et al.Blood|December 25, 2009
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Eva Hoster, Marie-Helene Delfau-Larue, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma NetworkEva Hoster, Andreas Rosenwald, Françoise Berger, et al.Pageof 21